WINTON GROUP Ltd Acquires New Position in Theravance Biopharma, Inc. $TBPH

WINTON GROUP Ltd acquired a new position in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) during the third quarter, Holdings Channel.com reports. The fund acquired 76,542 shares of the biopharmaceutical company’s stock, valued at approximately $1,118,000.

Other hedge funds have also recently made changes to their positions in the company. Tower Research Capital LLC TRC grew its position in Theravance Biopharma by 18.5% during the second quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock valued at $55,000 after acquiring an additional 781 shares during the last quarter. SG Americas Securities LLC bought a new position in shares of Theravance Biopharma in the 3rd quarter worth about $101,000. AQR Capital Management LLC bought a new position in Theravance Biopharma in the 1st quarter worth about $101,000. Creative Planning purchased a new stake in shares of Theravance Biopharma during the second quarter valued at $139,000. Finally, Engineers Gate Manager LP purchased a new position in shares of Theravance Biopharma during the second quarter valued at approximately $151,000. 99.10% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

TBPH has been the subject of a number of recent research reports. Wall Street Zen downgraded Theravance Biopharma from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 3rd. Weiss Ratings restated a “hold (c)” rating on shares of Theravance Biopharma in a research report on Thursday, January 22nd. HC Wainwright raised their price target on shares of Theravance Biopharma from $20.00 to $27.00 and gave the stock a “buy” rating in a research note on Monday, March 2nd. Oppenheimer cut shares of Theravance Biopharma from an “outperform” rating to a “market perform” rating in a report on Thursday, March 5th. Finally, BTIG Research reduced their price objective on shares of Theravance Biopharma from $40.00 to $21.00 and set a “buy” rating for the company in a research note on Tuesday, March 3rd. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $22.60.

Theravance Biopharma Price Performance

Shares of TBPH opened at $13.81 on Thursday. Theravance Biopharma, Inc. has a 1-year low of $7.90 and a 1-year high of $21.03. The firm has a 50-day simple moving average of $18.66 and a two-hundred day simple moving average of $16.86. The stock has a market cap of $699.75 million, a PE ratio of 24.23 and a beta of 0.17.

Theravance Biopharma Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.